Managing Obesity

Guides comprehensive obesity management with BMI tracking, lifestyle interventions, medication options, and surgical referral criteria.

Why This Skill Exists

Obesity (BMI ≥30 kg/m²) affects 42.4% of U.S. adults and is a primary driver of type 2 diabetes, cardiovascular disease, obstructive sleep apnea, NAFLD, osteoarthritis, and at least 13 types of cancer. Despite its prevalence, obesity is under-diagnosed (BMI often not calculated), under-discussed (clinicians avoid the topic), and under-treated (fewer than 3% of eligible patients receive anti-obesity medications). The American Medical Association recognized obesity as a disease in 2013, and CMS covers intensive behavioral therapy (IBT) for Medicare beneficiaries.

The treatment landscape has transformed with GLP-1 receptor agonists and GIP/GLP-1 dual agonists demonstrating 15-25% total body weight loss in clinical trials—approaching surgical outcomes. This skill provides a structured framework for diagnosis, lifestyle intervention, pharmacotherapy, and surgical referral that aligns with the Endocrine Society, AGA, and AAP guidelines for evidence-based obesity management.

Checkpoint A: Pre-Draft Intake (Mandatory)

What is the patient's current BMI (height and weight)? Default: calculate from vitals
What is the patient's waist circumference? Default: measure if BMI 25-34.9
What obesity-related comorbidities are present (T2DM, HTN, dyslipidemia, OSA, NASH, OA)? Default: per problem list
Has the patient attempted prior weight loss (methods, duration, results)? Default: unknown
Is the patient on medications that promote weight gain (insulin, sulfonylureas, antipsychotics, TCA, steroids, beta-blockers)? Default: per med list
Has the patient been screened for secondary causes of obesity (hypothyroidism, Cushing syndrome)? Default: no
What is the patient's readiness for change (pre-contemplation, contemplation, preparation, action, maintenance)? Default: assess
Does the patient have access to nutritionist, exercise facilities, or behavioral health? Default: assess

Documents to Request

Weight trend over past 2-5 years (EHR growth chart or weight log)
BMI history with prior documented interventions
Dietary history or food diary (3-day or 7-day recall)
Physical activity assessment (type, frequency, duration)
Labs: fasting glucose or A1c, lipid panel, LFTs (for NAFLD), TSH
Sleep study or STOP-BANG if OSA suspected
Prior medication trials for weight management with response
Bariatric surgery consultation notes if prior evaluation

Step 1: Classification and Comorbidity Assessment

| BMI Category | Classification | Waist Circumference Risk | |---|---|---| | 18.5-24.9 | Normal weight | N/A | | 25.0-29.9 | Overweight | ≥40 in (M) / ≥35 in (F) = elevated risk | | 30.0-34.9 | Class I obesity | Comorbidity assessment required | | 35.0-39.9 | Class II obesity | Pharmacotherapy indicated; surgical evaluation if comorbidities | | ≥40.0 | Class III obesity (severe) | Pharmacotherapy + surgical referral recommended |

Edmonton Obesity Staging System (assesses functional impact):

Stage 0: No risk factors, no symptoms
Stage 1: Subclinical risk factors (prediabetes, elevated BP)
Stage 2: Established disease (T2DM, HTN, OSA, GERD, PCOS)
Stage 3: End-organ damage (MI, HF, OSA with pulmonary hypertension)
Stage 4: Severe disability, end-stage disease

Screen for secondary causes if clinical suspicion:

TSH (hypothyroidism)
Morning cortisol or overnight dexamethasone suppression (Cushing syndrome)
Consider PCOS workup in reproductive-age women (testosterone, DHEAS)

Step 2: Intensive Lifestyle Intervention (Foundation)

All patients with BMI ≥25 should receive structured lifestyle counseling:

Dietary approach (no single diet is superior; adherence predicts success):

Caloric deficit: 500-750 kcal/day below estimated needs for 1-1.5 lb/week loss
Mediterranean, DASH, low-carbohydrate, or volumetric approaches all effective
Meal timing: regular meals, avoid late-night eating
Portion control using plate method: ½ vegetables, ¼ protein, ¼ whole grains
Limit sugar-sweetened beverages, ultra-processed foods, and alcohol

Physical activity:

Target: 150-300 minutes/week moderate-intensity aerobic exercise
Resistance training 2-3 sessions/week for lean mass preservation
Start with achievable goals (e.g., 10-minute walks 3x/day) and progress
Activity tracking (pedometer, fitness tracker) improves adherence

Behavioral strategies:

Self-monitoring (food diary, weigh daily/weekly)
Stimulus control (remove trigger foods, portion pre-plating)
Cognitive restructuring (address all-or-nothing thinking)
Refer to intensive behavioral therapy (IBT): ≥14 sessions in 6 months per CMS coverage for Medicare
Consider commercial programs with evidence base (e.g., WW, Noom)

Target: 5-10% total body weight loss at 6 months. Even 3-5% loss produces clinically meaningful improvements in glycemia, triglycerides, and blood pressure.

Step 3: Anti-Obesity Pharmacotherapy

Indicated when BMI ≥30, or BMI ≥27 with weight-related comorbidity, and lifestyle alone insufficient after 6 months:

| Agent | Mechanism | Expected Weight Loss | Key Considerations | |---|---|---|---| | Semaglutide 2.4mg SQ weekly (Wegovy) | GLP-1 RA | 15-17% TBW (STEP trials) | GI side effects; titrate over 16 weeks; contraindicated in MTC/MEN2 | | Tirzepatide SQ weekly (Zepbound) | GIP/GLP-1 dual agonist | 20-25% TBW (SURMOUNT trials) | GI side effects; titrate per protocol; supply constraints | | Liraglutide 3.0mg SQ daily (Saxenda) | GLP-1 RA | 5-8% TBW | Lower efficacy than semaglutide; daily injection | | Phentermine-topiramate ER (Qsymia) | Sympathomimetic + anticonvulsant | 8-10% TBW | REMS program; avoid in pregnancy (teratogenic); CV risk with phentermine | | Naltrexone-bupropion ER (Contrave) | Opioid antagonist + NDRI | 5-6% TBW | Cannot use with opioids; BP monitoring; seizure risk | | Orlistat (Alli/Xenical) | Lipase inhibitor | 3-5% TBW | GI side effects (steatorrhea); low efficacy; OTC available |

Assessment at 12-16 weeks:

If <5% TBW loss: re-evaluate adherence, consider dose escalation or switch
If ≥5% TBW loss: continue; reassess at 6 months and annually
Duration: long-term/chronic therapy recommended; weight regain expected upon discontinuation

Step 4: Bariatric Surgery Referral

NIH/ASMBS indications:

BMI ≥40 (regardless of comorbidities)
BMI ≥35 with at least one obesity-related comorbidity (T2DM, HTN, OSA, NASH, OA)
Updated ASMBS 2022 consensus: consider for BMI ≥30 with metabolic disease uncontrolled by medical therapy

| Procedure | Mechanism | Expected Weight Loss | Mortality Rate | |---|---|---|---| | Roux-en-Y gastric bypass (RYGB) | Restrictive + malabsorptive | 25-35% TBW at 2 years | 0.1-0.3% | | Sleeve gastrectomy | Restrictive (80% stomach removed) | 20-25% TBW at 2 years | 0.1% | | Adjustable gastric band | Restrictive (band) | 10-15% TBW (declining use) | 0.05% | | Biliopancreatic diversion with DS | Primarily malabsorptive | 35-45% TBW | 0.5-1% |

Pre-surgical requirements (varies by payer):

3-6 months of documented medically supervised weight management
Psychological evaluation
Nutritional counseling
Sleep study (most surgeons require)
Upper endoscopy (prior to RYGB to assess for H. pylori, Barrett's)

Checkpoint B: Post-Draft Alignment (Mandatory)

Is BMI calculated and classified with Edmonton staging?
Have secondary causes of obesity been considered and screened?
Is an intensive lifestyle intervention plan documented with specific targets?
Has pharmacotherapy been offered to eligible patients with rationale for agent selection?
Has bariatric surgery been discussed for patients meeting NIH criteria?

Quality Audit

[ ] BMI calculated from measured height and weight (not patient-reported)
[ ] Obesity classified by WHO category with documentation in problem list
[ ] Weight-related comorbidities listed and linked to obesity diagnosis
[ ] Secondary causes screened (TSH minimum; cortisol if clinical suspicion)
[ ] Weight-promoting medications identified and alternatives considered
[ ] Dietary counseling documented with specific approach recommended
[ ] Physical activity prescription documented with frequency, duration, and type
[ ] Referral to registered dietitian or structured program offered
[ ] Anti-obesity medication discussed if BMI ≥30 (or ≥27 with comorbidity)
[ ] Pharmacotherapy response assessed at 12-16 weeks with decision to continue/switch
[ ] Bariatric surgery referral discussed for eligible patients
[ ] Weight loss target set (5-10% TBW at 6 months)
[ ] Weight trend tracked over multiple visits
[ ] Motivational interviewing approach documented (readiness to change assessed)

Guidelines

Always calculate BMI from measured height and weight at every visit; patient-reported values are unreliable by an average of 2-3 BMI points
Use person-first language ("patient with obesity" not "obese patient") per AMA and Endocrine Society recommendations
BMI has known limitations: does not distinguish fat from muscle mass, and cutoffs may underestimate obesity risk in South Asian and East Asian populations (consider lower thresholds: overweight ≥23, obese ≥27.5)
Anti-obesity medications are chronic therapy; discontinuation typically results in weight regain of 50-100% within 1-2 years
GLP-1 RA and GIP/GLP-1 agonists require slow titration to minimize GI side effects; never start at full dose
Patients on GLP-1 RA must be counseled on the potential for delayed gastric emptying and aspiration risk under anesthesia—coordinate with anesthesia if surgery planned
Weight stigma in healthcare is well-documented and harmful; approach weight discussions with empathy, ask permission, and focus on health behaviors rather than numbers
Medicare covers intensive behavioral therapy (IBT) for obesity (G0473) when provided by a primary care clinician in the primary care setting